Josep Dalmau

List of Publications by Year in descending order

421 papers	53,097 citations	1299 109 h-index	1496 219 g-index
441 all docs	441 docs citations	441 times ranked	14602 citing authors

#	Article	IF	Citations
1	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
2	Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology, The, 2008, 7, 1091-1098.	4.9	2,696
3	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurology, The, 2013, 12, 157-165.	4.9	2,382
4	Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology, 2007, 61, 25-36.	2.8	2,166
5	Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology, The, 2011, 10, 63-74.	4.9	2,039
6	Antiâ€“Nâ€methylâ€Dâ€aspartate receptor (NMDAR) encephalitis in children and adolescents. Annals of Neurology, 2009, 66, 11-18.	2.8	969
7	Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis. Journal of Neuroscience, 2010, 30, 5866-5875.	1.7	959
8	Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurology, The, 2010, 9, 776-785.	4.9	947
9	Antibody-Mediated Encephalitis. New England Journal of Medicine, 2018, 378, 840-851.	13.9	812
10	Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurology, The, 2010, 9, 67-76.	4.9	805
11	Paraneoplastic syndromes of the CNS. Lancet Neurology, The, 2008, 7, 327-340.	4.9	772
12	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurology, The, 2014, 13, 167-177.	4.9	758
13	Anti-Hu-Associated Paraneoplastic Encephalomyelitis/Sensory Neuronopathy A Clinical Study of 71 Patients. Medicine (United States), 1992, 71, 59-72.	0.4	732
14	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Annals of Neurology, 2009, 65, 424-434.	2.8	712
15	Clinical analysis of anti-Ma2-associated encephalitis. Brain, 2004, 127, 1831-1844.	3.7	681
16	The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. Clinical Infectious Diseases, 2012, 54, 899-904.	2.9	619
17	Extreme delta brush. Neurology, 2012, 79, 1094-1100.	1.5	614
18	HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal. Cell, 1991, 67, 325-333.	13.5	572

#	Article	IF	Citations
19	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurology, The, 2014, 13, 276-286.	4.9	525
20	Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of Neurology, 2005, 58, 594-604.	2.8	516
21	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurology, The, 2019, 18, 1045-1057.	4.9	497
22	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology, 2011, 18, 19.	1.7	489
23	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurology, The, 2014, 13, 575-586.	4.9	436
24	Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain, 2005, 128, 1764-1777.	3.7	434
25	Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiological Reviews, 2017, 97, 839-887.	13.1	428
26	Neuronal autoantigensâ€"pathogenesis, associated disorders and antibody testing. Nature Reviews Neurology, 2012, 8, 380-390.	4.9	424
27	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurology, The, 2018, 17, 760-772.	4.9	422
28	Encephalitis and GABA _B receptor antibodies. Neurology, 2013, 81, 1500-1506.	1.5	412
29	Overlapping demyelinating syndromes and antiâ€"Nâ€methylâ€Dâ€aspartate receptor encephalitis. Annals of Neurology, 2014, 75, 411-428.	2.8	405
30	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain, 2015, 138, 94-109.	3.7	391
31	Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology, 2011, 77, 179-189.	1.5	379
32	Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer?A quantitative western blot analysis. Annals of Neurology, 1990, 27, 544-552.	2.8	375
33	Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Annals of Neurology, 2014, 75, 317-323.	2.8	372
34	Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Annals of Neurology, 2011, 69, 303-311.	2.8	371
35	Pediatric Anti-N-methyl-D-Aspartate Receptor Encephalitisâ€"Clinical Analysis and Novel Findings in a Series of 20 Patients. Journal of Pediatrics, 2013, 162, 850-856.e2.	0.9	362
36	A Serologic Marker of Paraneoplastic Limbic and Brain-Stem Encephalitis in Patients with Testicular Cancer. New England Journal of Medicine, 1999, 340, 1788-1795.	13.9	356

#	Article	IF	Citations
37	Frequency and Characteristics of Isolated Psychiatric Episodes in Antiâ€“N-Methyl-<scp>d</scp>-Aspartate Receptor Encephalitis. JAMA Neurology, 2013, 70, 1133.	4.5	354
38	Nâ€methylâ€<scp>D</scp>âaspartate receptor antibodies in herpes simplex encephalitis. Annals of Neurology, 2012, 72, 902-911.	2.8	343
39	Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment. Neurologist, 2007, 13, 261-271.	0.4	339
40	Antibodies and neuronal autoimmune disorders of the CNS. Journal of Neurology, 2010, 257, 509-517.	1.8	338
41	The clinical spectrum of Caspr2 antibodyâ€“associated disease. Neurology, 2016, 87, 521-528.	1.5	327
42	Autoimmune encephalopathies. Annals of the New York Academy of Sciences, 2015, 1338, 94-114.	1.8	322
43	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	313
44	Encephalitis and AMPA receptor antibodies. Neurology, 2015, 84, 2403-2412.	1.5	311
45	Encephalitis and antibodies to dipeptidylâ€peptidaseâ€like proteinâ€6, a subunit of Kv4.2 potassium channels. Annals of Neurology, 2013, 73, 120-128.	2.8	305
46	Clinical manifestations of the anti-IgLON5 disease. Neurology, 2017, 88, 1736-1743.	1.5	300
47	Cognitive deficits following anti-NMDA receptor encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 195-198.	0.9	297
48	Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathologica, 2009, 118, 737-743.	3.9	296
49	Selective Expression of Purkinje-Cell Antigens in Tumor Tissue from Patients with Paraneoplastic Cerebellar Degeneration. New England Journal of Medicine, 1990, 322, 1844-1851.	13.9	287
50	Acute mechanisms underlying antibody effects in antiâ€“Nâ€methylâ€Dâ€aspartate receptor encephalitis. Annals of Neurology, 2014, 76, 108-119.	2.8	287
51	Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology, 2014, 82, 879-886.	1.5	285
52	Anti-LGI1â€“associated cognitive impairment. Neurology, 2016, 87, 759-765.	1.5	264
53	Investigations in GABA _A receptor antibody-associated encephalitis. Neurology, 2017, 88, 1012-1020.	1.5	257
54	Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Annals of Neurology, 2001, 50, 339-348.	2.8	256

#	Article	IF	Citations
55	Anti-NMDA Receptor Encephalitis Antibody Binding Is Dependent on Amino Acid Identity of a Small Region within the GluN1 Amino Terminal Domain. Journal of Neuroscience, 2012, 32, 11082-11094.	1.7	247
56	A patient with encephalitis associated with NMDA receptor antibodies. Nature Clinical Practice Neurology, 2007, 3, 291-296.	2.7	245
57	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Multiple Sclerosis Journal, 2015, 21, 866-874.	1.4	241
58	Autoimmune postâ€“herpes simplex encephalitis of adults and teenagers. Neurology, 2015, 85, 1736-1743.	1.5	226
59	Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain, 1999, 122, 27-39.	3.7	219
60	Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. Journal of Neuroimmunology, 2011, 231, 86-91.	1.1	209
61	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurology, The, 2020, 19, 234-246.	4.9	207
62	Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. Journal of Neuroimmunology, 1997, 74, 55-61.	1.1	204
63	Update on neurological paraneoplastic syndromes. Current Opinion in Oncology, 2015, 27, 489-495.	1.1	192
64	The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nature Reviews Neurology, 2017, 13, 290-301.	4.9	186
65	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2019, 16, 535-548.	12.5	186
66	A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology, 2019, 92, e244-e252.	1.5	183
67	Glycine Receptor Autoimmune Spectrum With Stiff-Man Syndrome Phenotype. JAMA Neurology, 2013, 70, 44.	4.5	180
68	Autoimmune Encephalitis in Children. Journal of Child Neurology, 2012, 27, 1460-1469.	0.7	178
69	NMDA receptor encephalitis and other antibody-mediated disorders of the synapse. Neurology, 2016, 87, 2471-2482.	1.5	178
70	Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	178
71	Motor neuron syndromes in cancer patients. Annals of Neurology, 1997, 41, 722-730.	2.8	175
72	Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathologica, 2016, 132, 531-543.	3.9	173

#	Article	IF	Citations
73	Herpes simplex virusâ€“1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report. Neurology, 2013, 81, 1637-1639.	1.5	171
74	DPPX antibodyâ€“associated encephalitis. Neurology, 2017, 88, 1340-1348.	1.5	170
75	Late-onset antiâ€“NMDA receptor encephalitis. Neurology, 2013, 81, 1058-1063.	1.5	169
76	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. JAMA Neurology, 2015, 72, 874.	4.5	169
77	Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 681-686.	0.9	166
78	Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophrenia Research, 2016, 176, 36-40.	1.1	163
79	Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites. Annals of Neurology, 1995, 38, 102-110.	2.8	162
80	Autoimmune encephalitis update. Neuro-Oncology, 2014, 16, 771-778.	0.6	162
81	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer, 1995, 75, 99-109.	2.0	159
82	Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy. Archives of Neurology, 2009, 66, 458-64.	4.9	158
83	T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology, 1998, 51, 1146-1150.	1.5	157
84	Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Annals of Neurology, 1999, 45, 162-167.	2.8	155
85	Interplay between persistent activity and activity-silent dynamics in the prefrontal cortex underlies serial biases in working memory. Nature Neuroscience, 2020, 23, 1016-1024.	7.1	154
86	Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurology, 2016, 73, 417.	4.5	152
87	Autoimmune seizures and epilepsy. Journal of Clinical Investigation, 2019, 129, 926-940.	3.9	152
88	Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Current Opinion in Neurology, 2014, 27, 361-368.	1.8	148
89	Anti-NMDA Receptor Encephalitis in Psychiatry. Current Psychiatry Reviews, 2011, 7, 189-193.	0.9	147
90	Paraneoplastic Neurologic Syndromes: Pathogenesis and Physiopathology. Brain Pathology, 1999, 9, 275-284.	2.1	145

#	Article	IF	Citations
91	Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood, 2014, 123, 3230-3238.	0.6	145
92	Investigations on CXCL13 in Antiâ€“N-Methyl-<scp>D</scp>-Aspartate Receptor Encephalitis. JAMA Neurology, 2015, 72, 180.	4.5	142
93	Paraneoplastic neurological syndromes. Current Opinion in Neurology, 2012, 25, 795-801.	1.8	139
94	Encephalitis with mGluR5 antibodies. Neurology, 2018, 90, e1964-e1972.	1.5	139
95	Autoantigen diversity in the opsoclonus-myoclonus syndrome. Annals of Neurology, 2003, 53, 347-353.	2.8	138
96	Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Current Opinion in Neurology, 2017, 30, 345-353.	1.8	138
97	Tonic seizures: A diagnostic clue of anti-LGI1 encephalitis?. Neurology, 2011, 76, 1355-1357.	1.5	135
98	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurology, 2016, 73, 714.	4.5	135
99	Ephrinâ€B2 prevents Nâ€methylâ€Dâ€aspartate receptor antibody effects on memory and neuroplasticity. Annals of Neurology, 2016, 80, 388-400.	2.8	134
100	GAD antibodies in neurological disorders â€” insights and challenges. Nature Reviews Neurology, 2020, 16, 353-365.	4.9	134
101	Antineuronal Antibodies in Patients With Neuroblastoma and Paraneoplastic Opsoclonus-Myoclonus. The American Journal of Pediatric Hematology/oncology, 2000, 22, 315-320.	1.3	129
102	Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity. PLoS ONE, 2015, 10, e0121364.	1.1	127
103	Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology, 2010, 75, 1480-1482.	1.5	125
104	Cellular plasticity induced by antiâ€“Î±â€aminoâ€3â€hydroxyâ€5â€methylâ€4â€isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Annals of Neurology, 2015, 77, 381-398.	2.8	122
105	Psychiatric Manifestations of Paraneoplastic Disorders. American Journal of Psychiatry, 2010, 167, 1039-1050.	4.0	120
106	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology, 2018, 90, e1386-e1394.	1.5	120
107	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor Î±1 Subunit in Patients With Isolated Optic Neuritis. JAMA Neurology, 2015, 72, 187.	4.5	119
108	Human neurexin-3Î± antibodies associate with encephalitis and alter synapse development. Neurology, 2016, 86, 2235-2242.	1.5	116

#	Article	IF	Citations
109	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. Annals of Clinical and Translational Neurology, 2014, 1, 822-832.	1.7	114
110	Immunological and pathological study of anti-Ri-associated encephalopathy. Annals of Neurology, 1994, 36, 896-902.	2.8	113
111	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Journal of Neurology, 2016, 263, 1349-1360.	1.8	112
112	LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain, 2018, 141, 3144-3159.	3.7	112
113	A Post-Transcriptional Regulatory Mechanism Restricts Expression of the Paraneoplastic Cerebellar Degeneration Antigen cdr2 to Immune Privileged Tissues. Journal of Neuroscience, 1997, 17, 1406-1415.	1.7	110
114	Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. Journal of Neurology, 2010, 257, 1686-1691.	1.8	106
115	Anti-DPPX encephalitis. Neurology, 2015, 85, 890-897.	1.5	106
116	Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. European Journal of Neuroscience, 2010, 32, 298-309.	1.2	104
117	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Annals of Neurology, 1999, 46, 774-777.	2.8	103
118	Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nature Communications, 2017, 8, 1791.	5.8	103
119	In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet Journal of Rare Diseases, 2010, 5, 31.	1.2	102
120	The Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 90-97.	0.9	102
121	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology, 2017, 4, 768-783.	1.7	101
122	Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology, 2017, 89, 1471-1475.	1.5	97
123	Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Current Opinion in Pediatrics, 2010, 22, 739-744.	1.0	95
124	Movement disorders in paraneoplastic and autoimmune disease. Current Opinion in Neurology, 2011, 24, 346-353.	1.8	94
125	Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. Journal of Neuroinflammation, 2016, 13, 226.	3.1	94
126	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology, 2020, 94, e2302-e2310.	1.5	94

#	Article	IF	Citations
127	Serum IgG Antibodies Against the NR₁Subunit of the NMDA Receptor Not Detected in Schizophrenia. American Journal of Psychiatry, 2012, 169, 1120-1121.	4.0	93
128	Cortactin autoantibodies in myasthenia gravis. Autoimmunity Reviews, 2014, 13, 1003-1007.	2.5	93
129	Hashimoto encephalopathy in the 21st century. Neurology, 2020, 94, e217-e224.	1.5	92
130	Use and Safety of Immunotherapeutic Management of N-Methyl-<scp>d</scp>-Aspartate Receptor Antibody Encephalitis. JAMA Neurology, 2021, 78, 1333.	4.5	91
131	Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction. Neuron, 2018, 100, 91-105.e9.	3.8	90
132	Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle and Nerve, 2000, 23, 1800-1818.	1.0	88
133	Paraneoplastic syndromes of the peripheral nerves. Current Opinion in Neurology, 2005, 18, 598-603.	1.8	88
134	Autoimmune Encephalitis in Postpartum Psychosis. American Journal of Psychiatry, 2015, 172, 901-908.	4.0	88
135	Neuro-Ophthalmologic Manifestations of Paraneoplastic Syndromes. Journal of Neuro-Ophthalmology, 2008, 28, 58-68.	0.4	83
136	Antiâ€"N-methyl-D-aspartate Receptor Encephalitis During Pregnancy. Archives of Neurology, 2010, 67, 884-7.	4.9	75
137	Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-<scp>d</scp>-Aspartate Receptor Encephalitis. JAMA Neurology, 2016, 73, 706.	4.5	74
138	NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?. Trends in Neurosciences, 2016, 39, 300-310.	4.2	73
139	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Multiple Sclerosis Journal, 2018, 24, 1753-1759.	1.4	71
140	Mechanisms of <scp>C</scp>aspr2 antibodies in autoimmune encephalitis and neuromyotonia. Annals of Neurology, 2018, 83, 40-51.	2.8	71
141	Neuronal molecular mimicry in immune-mediated neurologic disease. Annals of Neurology, 1998, 44, 87-98.	2.8	70
142	Antiâ€"Nâ€methylâ€<scp>D</scp>â€aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. Arthritis and Rheumatism, 2011, 63, 2516-2522.	6.7	70
143	Paraneoplastic syndromes and autoimmune encephalitis. Neurology: Clinical Practice, 2012, 2, 215-223.	0.8	70
144	Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. PLoS ONE, 2013, 8, e60438.	1.1	70

#	Article	IF	Citations
145	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	70
146	Antiâ€“NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders. Current Treatment Options in Neurology, 2011, 13, 324-332.	0.7	69
147	Cloning and characterization of a lambert-eaton myasthenic syndrome antigen. Annals of Neurology, 1993, 33, 113-120.	2.8	68
148	Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Research, 2017, 129, 101-105.	0.8	67
149	Persistent Intrathecal Antibody Synthesis 15 Years After Recovering From Antiâ€“ N-methyl-D-aspartate Receptor Encephalitis. JAMA Neurology, 2013, 70, 117.	4.5	66
150	Childhood Onset of Stiff-Man Syndrome. JAMA Neurology, 2013, 70, 1531.	4.5	65
151	Status epilepticus of inflammatory etiology. Neurology, 2015, 85, 464-470.	1.5	64
152	Sleep disorders in autoimmune encephalitis. Lancet Neurology, The, 2020, 19, 1010-1022.	4.9	64
153	Neuro-ophthalmology and paraneoplastic syndromes. Current Opinion in Neurology, 2004, 17, 3-8.	1.8	63
154	Aggressive Course in Encephalitis With Opsoclonus, Ataxia, Chorea, and Seizures. JAMA Neurology, 2014, 71, 620.	4.5	63
155	Autoimmunity, seizures, and status epilepticus. Epilepsia, 2013, 54, 46-49.	2.6	62
156	Antigenic and mechanistic characterization of antiâ€•<scp>AMPA</scp> receptor encephalitis. Annals of Clinical and Translational Neurology, 2014, 1, 180-189.	1.7	62
157	Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e136.	3.1	62
158	Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nature Clinical Practice Neurology, 2007, 3, 405-410.	2.7	61
159	NMDA Receptor Autoantibodies in Autoimmune Encephalitis Cause a Subunit-Specific Nanoscale Redistribution of NMDA Receptors. Cell Reports, 2018, 23, 3759-3768.	2.9	61
160	Effects of <scp>IgLON5</scp> Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Annals of Neurology, 2020, 88, 1023-1027.	2.8	61
161	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology, 2020, 95, e3012-e3025.	1.5	60
162	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 74.	4.5	59

#	Article	IF	Citations
163	Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathologica, 1998, 96, 1-7.	3.9	58
164	Neuronal Surface Antibody-Mediated Autoimmune Encephalitis. Seminars in Neurology, 2014, 34, 458-466.	0.5	57
165	P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. , 1999, 22, 119-122.		56
166	Autoimmune Encephalitis. European Neurological Review, 2012, 8, 31.	0.5	56
167	TREATMENT-RESPONSIVE SUBACUTE LIMBIC ENCEPHALITIS AND NMDA RECEPTOR ANTIBODIES IN A MAN. Neurology, 2008, 70, 728-729.	1.5	55
168	Patient With Homer-3 Antibodies and Cerebellitis. JAMA Neurology, 2013, 70, 506.	4.5	55
169	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	55
170	Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. Canadian Journal of Neurological Sciences, 2003, 30, 269-271.	0.3	54
171	Clinical significance of Kelch-like protein 11 antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	54
172	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, e61-e75.	1.5	54
173	Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia, 2009, 50, 58-60.	2.6	53
174	Characterization of the sleep disorder of anti-IgLON5 disease. Sleep, 2019, 42, .	0.6	52
175	Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. Journal of Neuroimmunology, 2007, 186, 177-180.	1.1	51
176	A novel treatmentâ€responsive encephalitis with frequent opsoclonus and teratoma. Annals of Neurology, 2014, 75, 435-441.	2.8	51
177	Prolonged Follow-up and CSF Antibody Titers in a Patient With Anti-NMDA Receptor Encephalitis. Neurology, 2011, 76, S64-6.	1.5	50
178	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology, 2021, 97, .	1.5	50
179	Diagnosis and Management of Paraneoplastic Neurologic Disorders. Current Treatment Options in Oncology, 2013, 14, 528-538.	1.3	49
180	Antibodies to Delta/Notch-like Epidermal Growth Factorâ€“Related Receptor in Patients With Anti-Tr, Paraneoplastic Cerebellar Degeneration, and Hodgkin Lymphoma. JAMA Neurology, 2014, 71, 1003.	4.5	49

#	Article	IF	Citations
181	Clinical and Immunological Diversity of Limbic Encephalitis: A Model for Paraneoplastic Neurologic Disorders. Hematology/Oncology Clinics of North America, 2006, 20, 1319-1335.	0.9	48
182	Paraneoplastic neuropathies. Current Opinion in Neurology, 2013, 26, 489-495.	1.8	48
183	Sleep disorders in anti-NMDAR encephalitis. Neurology, 2020, 95, e671-e684.	1.5	47
184	ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. Journal of Neuroimmunology, 2008, 201-202, 163-165.	1.1	46
185	Isolated hemidystonia associated with NMDA receptor antibodies. Movement Disorders, 2011, 26, 351-352.	2.2	46
186	Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. Frontiers in Immunology, 2021, 12, 691536.	2.2	46
187	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	44
188	Mouse model of anti-NMDA receptor postâ€“herpes simplex encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e529.	3.1	44
189	The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neuroscience Letters, 1993, 150, 212-214.	1.0	43
190	EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report. Journal of Neuro-Oncology, 2006, 81, 71-74.	1.4	43
191	Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma. Cancer, 2001, 91, 1423-1428.	2.0	42
192	Paraneoplastic neurologic syndromes. Neurologic Clinics, 2003, 21, 221-247.	0.8	42
193	Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. Journal of Neuroimmunology, 2013, 261, 53-59.	1.1	42
194	Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem. , 2013, 32, 251-254.		42
195	Paraneoplastic anti-Hu serum: studies on human tumor cell lines. Journal of Neuroimmunology, 1997, 79, 202-210.	1.1	41
196	Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. Nature Clinical Practice Neurology, 2006, 2, 566-572.	2.7	41
197	Orthostatic myoclonus associated with Caspr2 antibodies. Neurology, 2016, 86, 1353-1355.	1.5	41
198	Paraneoplastic Neurologic Syndromes. Neurologic Clinics, 2018, 36, 675-685.	0.8	41

#	Article	IF	Citations
199	Neuroimmune disorders of the central nervous system in children in the molecular era. Nature Reviews Neurology, 2018, 14, 433-445.	4.9	41
200	Paraneoplastic syndromes. Current Opinion in Immunology, 1997, 9, 723-729.	2.4	40
201	DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. Oncogene, 1999, 18, 2589-2597.	2.6	40
202	Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. Neurology, 2014, 82, 550-551.	1.5	40
203	Paraneoplastic Neurologic Syndromes: Approaches to Diagnosis and Treatment. Seminars in Neurology, 2003, 23, 215-224.	0.5	39
204	Metastases to the peripheral nervous system. Journal of Neuro-Oncology, 2005, 75, 101-110.	1.4	39
205	Update on Paraneoplastic and Autoimmune Disorders of the Central Nervous System. Seminars in Neurology, 2010, 30, 320-331.	0.5	39
206	An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays. PLoS ONE, 2013, 8, e79083.	1.1	39
207	Encefalitis por anticuerpos contra el receptor de NMDA. Medicina ClÃnica, 2018, 151, 71-79.	0.3	39
208	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	39
209	Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia. Nature Communications, 2020, 11, 4250.	5.8	38
210	Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: Detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. Annals of Neurology, 1999, 45, 805-809.	2.8	37
211	Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Movement Disorders, 2007, 22, 728-731.	2.2	37
212	Prevalence and treatment of anti-NMDA receptor encephalitis â€“ Authors' reply. Lancet Neurology, The, 2013, 12, 425-426.	4.9	37
213	Paraneoplastic neurological syndromes: diagnosis and treatment. Current Opinion in Internal Medicine, 2008, 7, 82-87.	1.5	36
214	Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. Journal of Neurology, 2011, 258, 27-33.	1.8	36
215	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. Journal of Neurology, 2011, 258, 1568-1570.	1.8	36
216	Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis. Brain, 2020, 143, 2709-2720.	3.7	36

#	Article	IF	Citations
217	Seizure-related 6 homolog like 2 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	36
218	Anti-Hu Immunolabeling as an Index of Neuronal Differentiation in Human Brain Tumors. American Journal of Surgical Pathology, 1998, 22, 195-200.	2.1	36
219	Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. Journal of the Neurological Sciences, 2006, 250, 153-155.	0.3	35
220	Serial brain 18FDG-PET in anti-AMPA receptor limbic encephalitis. Journal of Neuroimmunology, 2014, 271, 53-55.	1.1	35
221	Neuropathological Variability within a Spectrum of <scp>NMDAR</scp>â€Encephalitis. Annals of Neurology, 2021, 90, 725-737.	2.8	35
222	Clinical neuropathology practice guide 5-2012: Updated guideline for the diagnosis of antineuronal antibodies. , 2012, 31, 337-341.		34
223	The Photoreceptor Cell-Specific Nuclear Receptor is an Autoantigen of Paraneoplastic Retinopathy. Journal of Neuro-Ophthalmology, 2001, 21, 168-172.	0.4	33
224	Anti-GAD Antibody Positive Stiff-Limb Syndrome in Multiple Myeloma. Journal of Neuro-Oncology, 2003, 65, 173-175.	1.4	33
225	Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. Journal of Neuroimmunology, 2015, 286, 86-92.	1.1	33
226	Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua. Journal of Neuro-Oncology, 2005, 72, 63-66.	1.4	32
227	Case 4-2007. New England Journal of Medicine, 2007, 356, 612-620.	13.9	32
228	Acute psychiatric illness in a young woman: an unusual form of encephalitis. Medical Journal of Australia, 2009, 191, 284-286.	0.8	32
229	Caspr2 autoantibodies target multiple epitopes. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e127.	3.1	32
230	When a serum test overrides the clinical assessment. Neurology, 2015, 84, 1379-1381.	1.5	32
231	Pseudo-Piano Playing Motions and Nocturnal Hypoventilation in Anti-NMDA Receptor Encephalitis: Response to Prompt Tumor Removal and Immunotherapy. Internal Medicine, 2011, 50, 627-630.	0.3	31
232	Antibodies to Nâ€methylâ€Dâ€aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms postâ€herpes virus encephalitis. Movement Disorders, 2014, 29, 3-6.	2.2	31
233	<scp>NMDAR</scp> Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice. Annals of Neurology, 2020, 88, 603-613.	2.8	31
234	The growing spectrum of antibody-associated inflammatory brain diseases in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e92.	3.1	30

#	Article	IF	Citations
235	Pregnancy outcomes in anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	30
236	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e659.	3.1	30
237	Current therapies for paraneoplastic neurologic syndromes. Current Treatment Options in Neurology, 2003, 5, 69-77.	0.7	29
238	Scleromyxedema and dermatoâ€“neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. American Journal of Hematology, 2011, 86, 893-896.	2.0	29
239	Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 630-634.	1.3	29
240	Acquired Neuromyotonia Heralding Recurrent Thymoma in Myasthenia Gravis. JAMA Neurology, 2013, 70, 1311-4.	4.5	29
241	Carbonic anhydraseâ€related protein <scp>VIII</scp> antibodies and paraneoplastic cerebellar degeneration. Neuropathology and Applied Neurobiology, 2014, 40, 650-653.	1.8	29
242	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	29
243	Hu Immunolabeling as a Marker of Neural and Neuroendocrine Differentiation in Normal and Neoplastic Human Tissues: Assessment Using a Recombinant Anti-Hu Fab Fragment. International Journal of Surgical Pathology, 2000, 8, 109-117.	0.4	28
244	Paraneoplastic disorders of eye movements. Annals of the New York Academy of Sciences, 2011, 1233, 279-284.	1.8	28
245	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology, 2017, 88, 1235-1242.	1.5	28
246	Nâ€Methylâ€Dâ€Aspartate Receptor Antibodies in Autoimmune Encephalopathy Alter Oligodendrocyte Function. Annals of Neurology, 2020, 87, 670-676.	2.8	28
247	Thymoma and Autoimmune Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	28
248	Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. , 1998, 21, 1358-1359.		27
249	Anti-NMDA-receptor encephalitis in a 3 year old patient with chromosome 6p21.32 microdeletion including the HLA cluster. European Journal of Paediatric Neurology, 2011, 15, 163-166.	0.7	27
250	Pitfalls in the detection of CV2 (CRMP5) antibodies. Journal of Neuroimmunology, 2016, 290, 80-83.	1.1	27
251	Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay. PLoS ONE, 2015, 10, e0122037.	1.1	27
252	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations. Frontiers in Immunology, 2019, 10, 769.	2.2	26

#	Article	IF	Citations
253	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. Annals of Neurology, 2021, 90, 101-117.	2.8	26
254	Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis. Journal of Neuroimmunology, 2015, 287, 31-35.	1.1	25
255	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis â€“ Authors' reply. Lancet Neurology, The, 2016, 15, 1010.	4.9	25
256	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.5	25
257	Anti-Hu antibodies in Merkel cell carcinoma. Annals of Neurology, 2002, 52, 111-115.	2.8	24
258	Anti-N-methyl-d-aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus. Journal of Neurology, 2011, 258, 1351-1353.	1.8	24
259	Paraneoplastic Neurologic Disorders in Children. Current Neurology and Neuroscience Reports, 2011, 11, 187-194.	2.0	24
260	Antiâ€“N-methyl-D-aspartate Receptor Encephalitis. Archives of Neurology, 2010, 67, 250-1.	4.9	24
261	Update on Paraneoplastic Neurologic Disorders. Oncologist, 2010, 15, 603-617.	1.9	23
262	Protein kinase CÎ³ antibodies and paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2013, 256, 91-93.	1.1	23
263	CNS autoimmunity: new findings and pending issues. Lancet Neurology, The, 2012, 11, 17-19.	4.9	22
264	Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 920-928.	0.9	22
265	A call for a global COVID-19 Neuro Research Coalition. Lancet Neurology, The, 2020, 19, 482-484.	4.9	22
266	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	1.1	21
267	Neuropathologic features of anti-dipeptidyl-peptidase-like protein-6 antibody encephalitis. Neurology, 2015, 84, 430-432.	1.5	20
268	Clinical enigmas of paraneoplastic neurologic disorders. Clinical Neurology and Neurosurgery, 1995, 97, 61-70.	0.6	19
269	The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. Annals of Neurology, 2003, 53, 123-127.	2.8	19
270	Reduced Nâ€acetylaspartate in the basal ganglia of a patient with antiâ€NMDA receptor encephalitis. Movement Disorders, 2009, 24, 784-786.	2.2	19

#	Article	IF	Citations
271	Update on paraneoplastic neurologic disorders. Community Oncology, 2010, 7, 219-224.	0.2	18
272	Toll-like receptor 3 deficiency in autoimmune encephalitis postâ€“herpes simplex encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e611.	3.1	18
273	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	0.9	18
274	p53 gene mutations in primary lung tumors are conserved in brain metastases. Journal of Neuro-Oncology, 1992, 14, 93-100.	1.4	17
275	Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2008, 193, 173-182.	1.1	17
276	Thymoma-associated paraneoplastic encephalitis (TAPE): Diagnosis and treatment of a potentially fatal condition. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, e17-e20.	0.4	17
277	Clinical Reasoning: Agitation and psychosis in a patient after renal transplantation. Neurology, 2012, 79, e41-4.	1.5	17
278	Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: Three new cases and a review of the literature. Journal of Neuroimmunology, 2019, 334, 576975.	1.1	17
279	Placental transfer of NMDAR antibodies causes reversible alterations in mice. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	17
280	Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex. Annals of Neurology, 2022, 91, 801-813.	2.8	17
281	<scp>ZSCAN1</scp> Autoantibodies Are Associated with Pediatric Paraneoplastic <scp>ROHHAD</scp>. Annals of Neurology, 2022, 92, 279-291.	2.8	17
282	Normalization of the Tumor Marker CA-125 after Oophorectomy in a Patient with Paraneoplastic Cerebellar Degeneration without Detectable Cancer. Gynecologic Oncology, 1997, 65, 173-176.	0.6	16
283	Inverse Ocular Bobbing in a Patient With Encephalitis Associated With Antibodies to the N-methyl-D-aspartate Receptor. Archives of Neurology, 2008, 65, 1251.	4.9	15
284	Perfusion ¹²³IMPâ€SPECT shows reversible abnormalities in GABA_B receptor antibody associated encephalitis with normal MRI. Brain and Behavior, 2011, 1, 70-72.	1.0	15
285	Glazed (Vision) and Confused. Survey of Ophthalmology, 2010, 55, 169-173.	1.7	14
286	Case 34-2011. New England Journal of Medicine, 2011, 365, 1825-1833.	13.9	14
287	Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). Journal of Neuroimmunology, 2016, 300, 15-17.	1.1	14
288	Neurological paraneoplastic syndromes. Seminars in Immunopathology, 1996, 18, 85-95.	4.0	13

#	Article	IF	Citations
289	Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. Journal of Neurology, 1997, 244, 333-335.	1.8	13
290	A case of slow orthostatic tremor, responsive to intravenous immunoglobulin. Movement Disorders, 2011, 26, 1563-1565.	2.2	13
291	Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	13
292	Considerations of psychotic symptomatology in antiâ€NMDA encephalitis: Similarity to cycloid psychosis. Clinical Case Reports (discontinued), 2019, 7, 2456-2461.	0.2	13
293	Ung jente med psykose, kognitiv svikt og kramper. Tidsskrift for Den Norske Laegeforening, 2012, 132, 2073-2076.	0.2	13
294	Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Pediatric Blood and Cancer, 2012, 58, 986-987.	0.8	12
295	Hodgkinâ€™s lymphoma associated with paraneoplastic cerebellar degeneration in children: a case report and review of the literature. Child's Nervous System, 2017, 33, 509-512.	0.6	12
296	Anti-N-methyl D-Aspartate Receptor Encephalitis Mimics Viral Encephalitis. Pediatric Infectious Disease Journal, 2012, 31, 202-204.	1.1	11
297	Antiâ€“Nâ€methylâ€Dâ€aspartateâ€glutamicâ€receptor encephalitis presenting as paroxysmal exerciseâ€induced foot weakness. Movement Disorders, 2013, 28, 820-822.	2.2	11
298	Encephalitis associated with antibodies against the NMDA receptor. Medicina ClÃnica (English Edition), 2018, 151, 71-79.	0.1	11
299	â€œAntibody of Unknown Significanceâ€•(AUS): The Issue of Interpreting Antibody Test Results. Movement Disorders, 2021, 36, 1543-1547.	2.2	11
300	Current therapies for neuromuscular manifestations of paraneoplastic syndromes. Current Neurology and Neuroscience Reports, 2006, 6, 77-84.	2.0	10
301	Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	10
302	Do we need to measure specific antibodies in patients with limbic encephalitis?. Neurology, 2017, 88, 508-509.	1.5	9
303	Spatial Suppression and Sensitivity for Motion in Schizophrenia. Schizophrenia Bulletin Open, 2020, 1, .	0.9	9
304	Autoimmune encephalitis or autoimmune psychosis?. European Neuropsychopharmacology, 2021, 50, 112-114.	0.3	9
305	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. Neurology, 2021, 96, e1082-e1087.	1.5	9
306	Human Metabotropic Glutamate Receptor 5 Antibodies Alter Receptor Levels and Behavior in Mice. Annals of Neurology, 2022, 92, 81-86.	2.8	9

#	Article	IF	Citations
307	Recognizing Paraneoplastic Limbic Encephalitis. Journal of Clinical Oncology, 2009, 27, e230-e231.	0.8	8
308	Paraneoplastic neurologic disorders: a brief overview. Memo - Magazine of European Medical Oncology, 2012, 5, 197-200.	0.3	8
309	Recognizing autoimmune encephalitis as a cause of seizures. Neurology, 2019, 92, 877-878.	1.5	8
310	Paraneoplastic Syndromes and Progressive Motor Dysfunction. Seminars in Neurology, 1993, 13, 291-298.	0.5	7
311	Paraneoplastic limbic encephalitis associated with small-cell lung cancer. Community Oncology, 2007, 4, 491-494.	0.2	6
312	Paraneoplastic syndromes causing movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 315-321.	1.0	6
313	Optic Neuritis in the Setting of NMDA Receptor Encephalitis. Journal of Neuro-Ophthalmology, 2014, 34, 316-319.	0.4	6
314	Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis. Journal of Neurology, 2022, 269, 2486-2492.	1.8	6
315	Antibody-mediated neuropsychiatric disorders. Journal of Allergy and Clinical Immunology, 2022, 149, 37-40.	1.5	6
316	[16] Characterization of neuronal antigens and antineuronal antibodies. Methods in Neurosciences, 1995, , 261-271.	0.5	5
317	Unusual neuro-ophthalmologic findings in a patient with anti-Yo-associated cerebellar degeneration. Journal of the Neurological Sciences, 2004, 225, 153-155.	0.3	5
318	Neuronal Antibodies in Creutzfeldt-Jakob Diseaseâ€"Reply. JAMA Neurology, 2014, 71, 514.	4.5	5
319	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?â€"Authors' reply. Lancet Neurology, The, 2014, 13, 864-865.	4.9	5
320	Anti-NMDA Receptor Encephalitis, Autoimmunity, and Psychosis. Focus (American Psychiatric) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	0.4	5
321	Precision in neuroimmunology. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e345.	3.1	5
322	The case for autoimmune neurology. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e373.	3.1	5
323	THE CLINICAL SPECTRM AND PATHOGENESIS OF PARANEOPLASTIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM. Hematology/Oncology Clinics of North America, 2001, 15, 1109-1128.	0.9	4
324	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. Laboratoriums Medizin, 2011, 35, 329-342.	0.1	4

#	Article	IF	Citations
325	Central nervous system paraneoplastic disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 853-864.	1.0	4
326	Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. BMJ Case Reports, 2009, 2009, bcr0720080509-bcr0720080509.	0.2	4
327	The E. Graeme Robertson Lecture. Journal of Clinical Neuroscience, 1996, 3, 8-15.	0.8	3
328	THYMOMA, MYASTHENIA GRAVIS, ENCEPHALITIS, AND A NOVEL ANTICYTOPLASMIC NEURONAL ANTIBODY. Neurology, 2007, 69, 1302-1303.	1.5	3
329	Laboratoriums Medizin, 2012, 35, ---.	0.1	3
330	Autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e181.	3.1	3
331	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	1.1	3
332	Acute disseminated encephalomyelitis: A rare autoimmune complication of herpes simplex encephalitis in the adult. Clinical Neurology and Neurosurgery, 2018, 175, 47-49.	0.6	3
333	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e925.	3.1	3
334	Herpes simplex encephalitis in a patient with cancer. Journal of Neuro-Oncology, 2006, 78, 211-211.	1.4	2
335	Paraneoplastic disorders of the memory and cognition. , 2009, , 377-394.		2
336	Laparoscopic epilepsy surgery. Intensive Care Medicine, 2010, 36, 367-368.	3.9	2
337	Complement-mediated cytotoxicity of antibodies to the GABAB receptor â€“ Authors' reply. Lancet Neurology, The, 2010, 9, 343-344.	4.9	2
338	Observations on the evolving fields of neuroimmunology and neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e67.	3.1	2
339	Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodiesâ€”Reply. JAMA Neurology, 2016, 73, 891.	4.5	2
340	Looks can be deceiving. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e461.	3.1	2
341	Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1061.	3.1	2
342	Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Annals of Neurology, 2001, 50, 339-348.	2.8	2

#	Article	IF	Citations
343	Paraneoplastic disorders of the nervous system. European Journal of Cancer, Supplement, 2007, 5, 53-67.	2.2	1
344	Paraneoplastic Syndromes of the Nervous System. , 2008, , 237-255.		1
345	Paraneoplastic disorders of the memory and cognition: clinical aspects and therapeutic approaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 873-876.	1.0	1
346	A multimodality approach to reversible paraneoplastic encephalitis associated with ovarian teratomas. Acta OncolÃ³gica, 2009, 48, 1079-1082.	0.8	1
347	Name a brain protein, and an autoantibody shall be found!. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e159.	3.1	1
348	Identifying targets for diagnosis, prognosis, and treatment. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e87.	3.1	1
349	Reply to: N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. Biological Psychiatry, 2016, 79, e63.	0.7	1
350	Author response: The clinical spectrum of Caspr2 antibody-associated disease. Neurology, 2017, 88, 333-334.	1.5	1
351	In vitroeffects of a human monoclonal antibody against theN-methyl-d-aspartate receptor. Brain, 2017, 140, e9-e9.	3.7	1
352	Paraneoplastic Syndromes of the Nervous System as Complications of Cancer. , 2018, , 221-238.		1
353	N2 year in review and message from the editor to our reviewers. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e525.	3.1	1
354	Pregnancy, Nâ€Methylâ€Dâ€Aspartate Receptor Antibodies, and Neuropsychiatric Diseases. Annals of Neurology, 2020, 87, 324-325.	2.8	1
355	A probable case of anti-NMDAR encephalitis from 1830. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	1
356	N2 in the time of COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e858.	3.1	1
357	Paraneoplastic Neurologic Syndromes. , 2020, , 676-687.e5.		1
358	Letter by Dalmau Regarding Article, â€œSerum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)â€• Stroke, 2020, 51, e28.	1.0	1
359	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e644.	3.1	1
360	Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. , 1999, 45, 162.		1

#	Article	IF	Citations
361	Paraneoplastic Syndromes of the Nervous System. , 2003, , 159-169.		1
362	Paraneoplastic Neurologic Syndromes. , 2008, , 767-778.		1
363	Cancer and the Nervous System. , 2012, , 1200-1210.		1
364	Author Response: Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, 1010-1010.	1.5	1
365	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
366	Pathogenesis and Disease Mechanisms in Neuronal Antibody-Mediated Encephalitis. , 2022, , 42-106.		1
367	Importance, Definitions, History, Classification, and Frequency of the Autoimmune Encephalitides. , 2022, , 1-18.		1
368	Autoimmune Psychosis. , 2022, , 503-526.		1
369	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
370	Psychiatric Manifestations of Autoimmune Encephalitis. , 2022, , 527-544.		1
371	Author Response: Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2022, 98, 906-906.	1.5	1
372	The use of paraffin-embedded tissue for detection of antineuronal antibodies. Acta Neuropathologica, 1997, 94, 300-301.	3.9	0
373	PARANEOPLASTIC DISORDERS OF THE NERVOUS SYSTEM. CONTINUUM Lifelong Learning in Neurology, 2005, 11, 69-92.	0.4	0
374	Paraneoplastic Disorders. Blue Books of Neurology, 2010, , 411-430.	0.1	0
375	Neurologic Complications of Cancer. Seminars in Neurology, 2010, 30, 215-216.	0.5	0
376	Paraneoplastic Neurological Disorders in Leukemia and Lymphoma. , 2012, , 329-344.		0
377	Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders. , 2013, , 289-303.		0
378	Paraneoplastic movement disorders. , 0, , 39-51.		0

#	Article	IF	Citations
379	Reply. Annals of Neurology, 2014, 76, 464-465.	2.8	0
380	The first anniversary issue. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e137.	3.1	0
381	A box of chocolates. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e234.	3.1	0
382	Complex relationships. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e262.	3.1	0
383	An interesting variety. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e201.	3.1	0
384	Alphabet soup. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e217.	3.1	0
385	Importance of clinical observations. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e442.	3.1	0
386	Message from the Editor to our Reviewers. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e426.	3.1	0
387	Horizontal saccadic palsy as a prominent symptom of anti-NMDAR encephalitis. Neurology: Clinical Practice, 2019, 11, 10.1212/CPJ.0000000000000750.	0.8	0
388	â€œTime to rechargeâ€• Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	0
389	How DIRS is refining concepts. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e677.	3.1	0
390	Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders. Current Clinical Neurology, 2022, , 271-291.	0.1	0
391	Reply to: Comparing <scp>VUS</scp> and <scp>AUS</scp>: Parallels and Differences in Neurogenetics and Neuroimmunology. Movement Disorders, 2021, 36, 2454-2456.	2.2	0
392	Paraneoplastic Syndromes, Central. , 2003, , 784-787.		0
393	Paraneoplastic Syndromes, Immunology. , 2003, , 787-790.		0
394	Paraneoplastic Syndromes. , 2003, , 1146-1156.		0
395	Remote Effects of Cancer: Treatment of Paraneoplastic Neurologic Syndromes. , 2006, , 274-280.		0
396	Paraneoplastic Neurological Disorders. , 2007, , 163-169.		0

#	Article	IF	Citations
397	Paraneoplastic Neurologic Syndromes. , 2007, , 517-533.		0
398	Paraneoplastic Neurologic Syndromes. , 2014, , 597-607.e4.		0
399	Transfer and Expression of Antioncogenes and Paraneoplastic Genes in Normal and Neoplastic Cells in Vitro and in Vivo. , 1995, , 275-VIII.		0
400	Neurological paraneoplastic syndromes. , 1996, , 203-213.		0
401	â€œThe more we knowâ€• Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	3.1	0
402	Fat embolism showing restriction on diffusion sequence in brain magnetic resonance imaging. Arquivos De Neuro-Psiquiatria, 2016, 74, 597-598.	0.3	0
403	Autoimmune Cerebellar Ataxias. , 2022, , 342-367.		0
404	Anti-NMDAR Encephalitis. , 2022, , 210-254.		0
405	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
406	Anti-IgLON5 Disease. , 2022, , 411-429.		0
407	Autoimmune Brainstem Encephalitis. , 2022, , 368-390.		0
408	Deconstructing Hashimoto Encephalopathy. , 2022, , 460-475.		0
409	CNS Syndromes at the Frontier of Autoimmune Encephalitis. , 2022, , 476-502.		0
410	Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, , 290-314.		0
411	Autoimmune Dementia: A Useful Term?. , 2022, , 611-629.		0
412	Seizures and Antibodies Against Surface Antigens. , 2022, , 255-289.		0
413	Abnormal Movements in Neurological Autoimmune Disorders. , 2022, , 545-562.		0
414	Immunity, Inflammation, and Epilepsy. , 2022, , 588-610.		0

#	Article	IF	Citations
415	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. , 2022, , 315-341.		0
416	Sleep and Autoimmunity. , 2022, , 563-587.		0
417	Limbic Encephalitis. , 2022, , 167-190.		0
418	Autoimmunity Against Proteins Associated with Voltage-Gated Potassium Channels. , 2022, , 191-209.		0
419	Antibodies to Intracellular Antigens in CNS Disorders. , 2022, , 107-134.		0
420	Autoimmunity Against the Inhibitory Synapsis. , 2022, , 391-410.		0
421	General Approach to Diagnosis. , 2022, , 19-41.		0